Section 5: Patient Safety and Quality Assurance

5PSQ-094

EFFICACY AND DURATION IN TREATMENT OF ACANTHAMOEBA KERATITIS. PREVALENCE AND RISK FACTOR OF THE INFECTION

5PSQ-093

ASSESSMENT TOOL FOR HOSPITAL ADMISSIONS RELATED TO MEDICATIONS, 10 QUESTIONS (ATHARM10): A VALIDATION STUDY

5PSQ-092

ANALYSIS OF OFF-LABEL USES OF INHALERS IN HOSPITALISED PATIENTS

5PSQ-091

IDENTIFY AND PROTOCOLISE TORSADE DE POINTES RISK IN A RESIDENTIAL CENTRE

5PSQ-083

STUDY OF THE PREVALENCE OF IMMUNOGENICITY IN PATIENTS TREATED WITH ANTI-TUMOUR NECROSIS FACTOR MONOCLONAL ANTIBODIES

5PSQ-080

EFFECTIVENESS AND SECURITY OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

5PSQ-079

ARE ANALYTICAL PARAMETERS SUITABLE PREDICTORS IN RHEUMATOLOGIC DISEASES?

5PSQ-076

PATIENT-REPORTED OUTCOMES IN MULTIPLE SCLEROSIS

5PSQ-074

ACTIVITY OF ENZALUTAMIDE AFTER ABIRATERONE IN CASTRATION-RESISTANT PROSTATE CANCER

5PSQ-071

EFFICACY AND SAFETY EVALUATION OF TRIFLURIDINE/TIPARACIL FOR METASTATIC COLON CANCER (MCRC)

5PSQ-064

USE OF SORAFENIB IN CELLULAR HEPATOCARCINOMA IN ROUTINE CLINICAL PRACTICE

5PSQ-063

RESPONSE TO ABIRATERONE AND ENZALUTAMIDE IN CASTRATE-RESISTANT PROSTATE CANCER IN CLINICAL PRACTICE

5PSQ-061

STABILITY OF CARBOPLATIN INFUSION SOLUTIONS USED IN DESENSITISATION PROTOCOL

5PSQ-058

COMPARATIVE EFFECTIVENESS OF REGORAFENIB VERSUS TRIFLURIDINE/TIPIRACIL IN METASTATIC COLORECTAL CANCER

5PSQ-056

EVALUATION OF OXALIPLATIN-SPECIFIC NEUROTOXICITY BASED ON TOTAL CUMULATIVE DOSE

Pages